Hepato Tablets

Hepato Tablets — Saturn Formulations PCD Pharma Franchise

Liver disease represents one of India's most significant public health challenges — with non-alcoholic fatty liver disease (NAFLD) affecting an estimated 9–32% of the general population, viral hepatitis B and C infecting tens of millions, alcohol-related liver disease rising with urbanisation, and drug-induced liver injury an increasingly recognised complication of polypharmacy in the country's ageing population. Hepatology and gastroenterology together generate substantial pharmaceutical prescription volumes for hepatoprotective, anti-inflammatory, antiviral, and bile acid-modifying medications. Saturn Formulations, a WHO-GMP and ISO-certified pharmaceutical manufacturer established in 2012, offers a comprehensive range of Hepato Tablets spanning ursodeoxycholic acid, silymarin formulations, essential phospholipids, antiviral hepatitis therapy, and multi-ingredient liver-support combinations — giving PCD Pharma Franchise partners a complete hepatology pharmaceutical portfolio.

Our hepato tablet formulations are developed by experienced pharmacologists and clinicians with specific expertise in liver disease management. Silymarin standardisation, phospholipid purity testing, and UDCA polymorphic form selection are among the formulation science decisions that distinguish pharmaceutical-grade hepatoprotective tablets from crude liver extract preparations. Every hepato tablet batch from Saturn Formulations is tested by NABL-accredited methods and released with a complete Certificate of Analysis — the quality documentation that gastroenterologists and hepatologists demand.

Why Choose Saturn Formulations for Hepato Tablet Franchise?

• NAFLD Epidemic: India's rapidly growing NAFLD burden — driven by sedentary lifestyle, high refined carbohydrate diet, and obesity — creates millions of new hepatoprotective prescriptions annually.
• Gastroenterologist and Hepatologist Prescribing: Hepato tablets are exclusively specialist-prescribed — creating high-value, long-term specialist prescriber relationships for franchise partners.
• Chronic Liver Disease Therapy: NAFLD management, primary biliary cholangitis (UDCA therapy), and viral hepatitis maintenance all require long-term daily medication — generating consistent monthly franchise revenue.
• Premium Silymarin and Phospholipid Formulations: Standardised silymarin extract and pharmaceutical-grade phospholipid products command premium MRPs significantly above crude liver extract tablets.
• WHO-GMP Manufacturing: Full regulatory compliance with comprehensive QA documentation for specialist prescriber acceptance.
• Monopoly Territory Rights: Exclusive hepatology franchise territory assignment.

Our Hepato Tablet Range

Ursodeoxycholic Acid (UDCA) Tablets

UDCA 150mg, 300mg, and 450mg tablets — the single most evidence-supported hepatoprotective pharmaceutical for primary biliary cholangitis, intrahepatic cholestasis of pregnancy, and gallstone dissolution therapy. UDCA is a naturally occurring bile acid that replaces hydrophobic toxic bile acids in the enterohepatic circulation, reduces liver enzyme elevation, and slows progression of cholestatic liver disease. Long-term UDCA therapy (months to years) generates consistent monthly prescription refills — one of the most predictable hepatology franchise revenue sources.

Silymarin (Milk Thistle) Tablets

Silymarin 70mg (Silybum marianum extract standardised to 70% silybin content) tablets for hepatocyte protection in NAFLD, alcoholic liver disease, and drug-induced hepatotoxicity. Silymarin 140mg tablets (double-strength) for moderate-to-severe liver enzyme elevation requiring higher hepatoprotective support. Silybin-Phosphatidylcholine complex (Silibinin-PC) tablets with 3.5x improved bioavailability over conventional silymarin — the pharmaceutical-standard form recommended for evidence-based hepatoprotection. These products are prescribed by gastroenterologists as first-line hepatoprotective adjuncts for patients with elevated ALT/AST from any cause.

Essential Phospholipid Tablets

Essential Phospholipids (EPL) 300mg tablets (Phosphatidylcholine from soya, containing Polyenylphosphatidylcholine) for NAFLD, alcoholic hepatitis, and drug-induced liver injury management — the liver membrane repair and regeneration agent widely prescribed in hepatology practice. EPL + Silymarin combination tablets for comprehensive hepatocyte membrane protection and antioxidant hepatoprotection. These combination products are among the highest-prescribed non-UDCA hepatoprotective agents in Indian gastroenterology practice.

Antiviral Hepatitis Tablets

Tenofovir Disoproxil Fumarate (TDF) 300mg tablets for chronic hepatitis B management — the WHO-recommended first-line antiviral with high genetic barrier to resistance. Entecavir 0.5mg and 1mg tablets for nucleoside-naive and lamivudine-resistant hepatitis B management. Ribavirin 200mg and 400mg tablets as component of hepatitis C therapy. These Schedule H antiviral hepatitis products establish franchise partners in the hepatology specialist supply channel with long-term treatment cohorts.

Multi-Ingredient Liver Support Tablets

UDCA + Silymarin combination tablet for dual hepatoprotective mechanism in NAFLD and cholestatic liver disease. N-Acetylcysteine (NAC) 600mg effervescent and regular tablets for paracetamol hepatotoxicity management and antioxidant liver protection. Betaine (TMG) 500mg tablets for reduction of liver fat in NAFLD by promoting methyl group donation in hepatocyte methionine metabolism. Vitamin E 400 IU tablets for antioxidant hepatoprotection in NASH (non-alcoholic steatohepatitis) — supported by multiple clinical trials as an effective adjunct in NASH management.

Cholesterol and Lipid Management for NAFLD

Atorvastatin 10mg and 20mg tablets for combined dyslipidaemia management in metabolic syndrome with NAFLD. Fenofibrate 145mg tablets for hypertriglyceridaemia correction in fatty liver disease. Omega-3 Fatty Acid (EPA + DHA) 1g soft gel tablets for triglyceride reduction in severe hypertriglyceridaemia associated with NAFLD. These lipid-modifying products complement the core hepatoprotective portfolio by addressing the metabolic drivers of NAFLD.

Quality Standards — Hepato Tablet Manufacturing

Silymarin tablet quality is critically dependent on the standardisation of the Silybum marianum extract to defined silybin and total silymarin content. Saturn Formulations' incoming QC laboratory verifies silymarin extract identity by TLC and content by HPLC before release for manufacturing — ensuring that every tablet delivers the specified hepatoprotective dose. UDCA tablets undergo polymorphic form verification (UDCA exists in multiple crystal forms with significantly different bioavailability) by X-ray powder diffraction (XRPD) to confirm the pharmaceutically active form is used. Phospholipid tablets undergo phosphatidylcholine content assay and peroxide value testing to verify lipid purity and oxidative stability.

All hepato tablets are manufactured in dedicated production areas separate from other pharmaceutical categories to prevent cross-contamination. Finished product HPLC content assay, dissolution profiling, and accelerated stability studies at 40°C/75%RH for 6 months confirm potency maintenance through shelf life under Indian tropical storage conditions.

Market Opportunity — Hepato Tablet Franchise

India's hepato-pharmaceutical market exceeds INR 4,000 crore and is growing at 10–12% annually driven by rising NAFLD prevalence, expanding hepatology specialist access, and growing hepatitis B and C treatment rates following improved diagnostic availability. UDCA alone represents a multi-hundred crore prescription market driven by primary biliary cholangitis management and the increasingly recognised role of UDCA in NASH management. The NAFLD market represents the fastest-growing hepatological indication, with new patients being diagnosed through routine health check-up ultrasound programmes across India's corporate workforce every quarter.

Start Your Hepato Tablet Franchise

1. Contact us: +91-8729000609 | enquiry.saturn@gmail.com
2. Select hepato tablet SKUs from our gastroenterology/hepatology catalogue
3. Submit Schedule H Drug License and GST documents
4. Confirm exclusive hepatology territory and sign franchise agreement
5. Receive products and hepatology specialist promotional materials including clinical data support

Saturn Formulations' Hepato Tablet franchise positions your business at the centre of India's fastest-growing liver disease management market, backed by a decade of pharmaceutical manufacturing excellence, WHO-GMP certification, and the clinical credibility that hepatologists and gastroenterologists demand. Contact us today at +91-8729000609 or email enquiry.saturn@gmail.com to begin your hepatology franchise journey with Saturn Formulations.